The news of Heller’s departure as executive vice president of business development comes on the heels of Bristol-Myers Squibb’s decision earlier this month to return a cancer drug to Exelixis (NASDAQ: EXEL). While the company said it would not continue research on that drug, XL-218, it has concentrated on another cancer drug that BMS gave back a year ago, cabozantinib, which the company could partner with a larger drug developer.
No comments:
Post a Comment